Deeper molecular insights, with faster turn-around time, for sooner decisions across the patient journey

Singapore, 30 April 2026 — Gene Solutions has announced major upgrades to their K-TRACK and K-4CARE portfolios, reinforcing their commitment to making precision oncology more practical and more accessible in real-world care. With more than 20,000 K-TRACK, K-4CARE tests performed across leading cancer centers, the company has seen the growing clinical relevance of comprehensive genomic, transcriptomic profiling (CGP, CGTP) and molecular residual disease (MRD) monitoring in helping doctors guide treatment decisions and follow patients over time.

As the use of CGP and MRD continues to expand in oncology practice, turnaround time remains an important clinical consideration. To help doctors and patients access actionable molecular insights more quickly and more easily, Gene Solutions has introduced a new Dual Profiling approach, developed by the company’s R&D team, across both K-TRACK and K-4CARE. The upgraded workflow now delivers results in as little as ~5 working days for CGP and ~8 working days for ctDNA-MRD monitoring.

At the center of the upgrade is Dual Profiling — a design that combines tumor tissue profiling with liquid biopsy profiling using two separate but complementary gene panels. This enables clinicians to benefit from both the foundational molecular profile from tumor tissue and a more current blood-based view of disease status during follow-up. The new liquid biopsy profiling panels include Thoracic (125 genes), Digestive (113 genes), and Breast & Gynecological (149 genes), supporting comprehensive analysis of SNVs, indels, amplifications, and gene fusions.

For patient monitoring, this approach is particularly meaningful because it supports a broader and more personalized view of ctDNA over time. Rather than depending only on mutations identified at the initial tumor profiling stage, the liquid biopsy panel adds a more real-time layer of molecular insight during follow-up, helping clinicians monitor treatment response, detect molecular relapses earlier, and identify emerging resistance mechanisms as the disease evolves. The upgraded workflow supports tracking of up to 50 personalized mutations for K-4CARE with a limit of detection of 0.005%, and up to 20 personalized mutations for K-TRACK with a limit of detection of 0.01%.

While Dual Profiling is the central innovation of this upgrade, the portfolio also includes expanded tissue-based profiling to further support treatment selection. K-4CARE now analyzes 515 DNA genes, while K-TRACK covers 164 DNA genes. The upgraded portfolios also integrate DPYD pharmacogenomic reporting to support safer fluoropyrimidine use.

Why this matters for patients

Gene Solutions believes these enhancements will help bring advanced molecular testing closer to routine clinical practice. Faster turnaround, broader detection, and more sensitive MRD monitoring can translate into better‑timed interventions and more confident follow‑up strategies.

“By shifting to hybridization-based dual tumor–liquid biopsy profiling, our precision oncology portfolio delivers not only a comprehensive and actionable molecular landscape at the initial test but also enables more robust monitoring throughout treatment using non‑invasive ctDNA analysis. This approach allows clinicians to longitudinally track clinically relevant alterations, such as EGFR mutations and MET amplification in lung cancer, ERBB2 amplification and ESR1 mutations in breast cancer, and KRAS/BRAF alterations in colorectal cancer. We believe that this methodological upgrade brings our test portfolio closer to real-world clinical practice, while simultaneously shortening turnaround time and enhancing clinical applicability.” said Dr. Duy Sinh Nguyen – Medical Director

Availability: Singapore, Vietnam, Brazil, China, India, Indonesia, Hong Kong, Malaysia, Philippines, Thailand, Türkiye, United States of America.